Stockholders of both Syros Pharmaceuticals Inc., based in Cambridge, Mass., and Bedminster’s TYME Technologies approved plans for a merger valued at approximately $60 million. As previously announced, ...

TYME Technologies is a new biotechnology company that develops “cancer metabolism-based therapies” or CMBTs. These treatments are designed to work across a wide range of diagnoses, solid tumors, ...

The TYME machine is returning to Wisconsin. Nearly 20 years after the last TYME ATM disappeared, Landmark Credit Union is bringing the name back as part of the marketing strategy for its new line of ...

Oh, Wisconsin-isms. There are many. We've tackled soda v. pop and bag v. bayyyg and where "bubbler" came from. Now, we're back at it again. This time, we've looked into stories and explanations behind ...

BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of ...

– Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- ...

4 months ago, I got a call. And so today, I write this story. With the holiday season approaching, it becomes easier to find those people and moments in your life that bring joy, gratitude, and hope.

Shares of Tyme Technologies soared as much as 127% on Wednesday. The company was granted additional patent claims for its product TYME-19 which can be used to treat COVID-19. "We believe that TYME-19 ...

Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike ...